P631: A PCR-BASED ASSAY FOR IGLV3-21R110 SCREENING CONFIRMS ITS PROGNOSTIC VALUE IN AN INDEPENDENT COHORT OF 613 PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA.
HemaSphere（2022）
1 Institute d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) | 3 Hospital Clinic of Barcelona | 5 Centro de Investigación Biomédica en Red de Cáncer (CIBERONC) | 7 Servicio de Hematología y Hemoterapia | 8 Servicio de Hematología
Abstract
Background: Recent studies have shown that expression of the immunoglobulin lambda light chain IGLV3-21 gene carrying a point mutation in the amino acid 110 (named IGLV3-21R110) defines a subset of chronic lymphocytic leukemia (CLL) with an intermediate epigenetic subtype and poor prognosis (Maity et al. PNAS, 2020; Nadeu et al. Blood, 2021). This mutation is found in up to 6.5% of patients with CLL at diagnosis and up to 18% of cases enrolled in clinical trials. In addition, IGLV3-21R110 seems to have prognostic value independently of the IGHV gene somatic hypermutation (SHM) status, stereotype subset #2, and disease stage, which makes it a promising prognostic biomarker. However, further studies on independent cohorts are needed to support its application in clinical practice. Aims: To develop a rapid detection method of the IGLV3-21R110 mutation and to assess its prognostic significance in a cohort of 613 previously unpublished CLL patients. Methods: A multiplex IGLV3-21R110 mutation-specific polymerase chain reaction (msPCR) assay was established in a cohort of 12 patients (including 6 IGLV3-21R110 mutated) and validated in 159 cases (including 7 mutated; Nadeu et al. Blood, 2021). This msPCR assay was applied on an independent cohort of 613 CLL patients (575 CLL, 38 monoclonal B-cell lymphocytosis). Clinical analyses were performed for time to first treatment (TTFT) and overall survival (OS) from time of diagnosis considering only cases diagnosed as CLL. Results: A msPCR approach was designed integrating two forward primers aligning to distinct regions of the IGLV3-21 gene and two R110-specific reverse primers matching the IGLJ1 and IGLJ2/3 genes, respectively. A third pair of primers targeting exon 9 of FBXW7 was used as an internal control. PCR conditions were set up on a cohort of 12 cases and subsequently validated on 159 previously published cases with 100% concordance. We then applied this msPCR assay to a cohort of 613 previously unpublished CLL patients and identified the R110 mutation in 22 (3.6%) cases, including 75% mutated IGHV (M-CLL) and 25% unmutated IGHV (U-CLL). Moreover, 84.6% of IGLV3-21R110 cases carried non-stereotyped immunoglobulin genes while the remaining stereotyped IGLV3-21R110 cases were subset #2. Ten of the IGLV3-21R110 cases were classified according to the epigenetic subtypes and all belonged to the intermediate CLL (i-CLL) subgroup. Clinically, M-CLL patients carrying the IGLV3-21R110 as well as i-CLL with IGLV3-21R110 had a shorter TTFT compared to M-CLL and i-CLL lacking IGLV3-21R110, respectively, and similar to U-CLL/naïve-like CLL (p<0.005). Multivariable analyses including IGLV3-21R110, disease stage, and IGHV gene SHM status or epigenetic subtypes confirmed the independent prognostic value of IGLV3-21R110 on TTFT (p<0.005). IGLV3-21R110 had also a prognostic impact on OS since M-CLL carrying the IGLV3-21R110 had shorter OS similar to that of U-CLL (Figure). Finally, we combined these novel data with those of our previously published 489 CLL cohort (Nadeu et al. Blood, 2021) (N total=1102). Clinical analyses of the whole cohort confirmed the independent prognostic value of IGLV3-21R110. Image:Summary/Conclusion: We have developed a reliable, easy-to-use msPCR assay suitable for IGLV3-21R110 screening in large cohorts. By applying this msPCR on a cohort of 613 CLL patients, our results corroborate the relevance of IGLV3-21R110 testing to improve the risk stratification of CLL patients in the clinical practice, especially within M-CLL and i-CLL subtypes.
MoreTranslated text
求助PDF
上传PDF
View via Publisher
AI Read Science
AI Summary
AI Summary is the key point extracted automatically understanding the full text of the paper, including the background, methods, results, conclusions, icons and other key content, so that you can get the outline of the paper at a glance.
Example
Background
Key content
Introduction
Methods
Results
Related work
Fund
Key content
- Pretraining has recently greatly promoted the development of natural language processing (NLP)
- We show that M6 outperforms the baselines in multimodal downstream tasks, and the large M6 with 10 parameters can reach a better performance
- We propose a method called M6 that is able to process information of multiple modalities and perform both single-modal and cross-modal understanding and generation
- The model is scaled to large model with 10 billion parameters with sophisticated deployment, and the 10 -parameter M6-large is the largest pretrained model in Chinese
- Experimental results show that our proposed M6 outperforms the baseline in a number of downstream tasks concerning both single modality and multiple modalities We will continue the pretraining of extremely large models by increasing data to explore the limit of its performance
Upload PDF to Generate Summary
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn
Chat Paper